Increased risk of Parkinson’s disease among patients with age-related macular degeneration

Chen, Po‐Yu; Wan, Lei; Chen, Chih Sheng; Chen, Jamie Jiin-Yi; Yen, Wu Ming; Chiu, Lu-Ting; Hu, Kai-Chieh; Tien, Peng-Tai; Lin, Hui‐Ju

doi:10.1186/s12886-021-02196-8

Cited by 13 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dry-type AMD patients were not included in these 3 studies and also AMD was not classi ed as early and late. In the retrospective cohort study of Chen et al, AMD patients were divided into 3 groups as neovascular, non-neovascular and unspeci ed [17]. During the analysis of AMD subtypes, there was no signi cant difference in the risk of PD.…”

Section: Discussionmentioning

confidence: 99%

“…A number of several molecular studies suggested that oxidative stress, chronic in ammation, impairment of the processing and degradation of dysfunctional cellular components, and alterations of neuronal homeostasis are common biological pathways of PD [14][15]. An increased risk of PD in neovascular type AMD patients has been shown in several studies [16][17][18]. Pathomechanisms that contribute to AMD may be associated with the development of Parkinson's disease because both seem to share similar pathogenesis pathways and common risk factors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the effect of Age-Related Macular Degeneration type and stage on the risk of Parkinson’s disease

Yaşar¹,

Gürlevik²,

Bilgeç³

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose To investigate the association of Parkinson’s Disease(PD) with Age-Related Macular Degeneration(AMD) type and stage. Methods Our prospective study, the dry-type AMD group consisted of 296 patients with early stage and 284 patients with late-stage. The neovascular AMD group included 285 early-stage and 277 late-stage patients. The control group consisted of 300 patients who were similar in terms of age and gender. AMD patients will be grouped as dry and neovascular type, as well as the early and late-stages. The patients were questioned about the use of drugs for PD, and the use was recorded as having the disease. In the absence of drug use, detailed inquiries were made for both diseases. If any of the complaints seen in the PD was present, the patient was referred to a neurologist, and the presence or absence of the PD was confirmed. Results PD was detected in 1% of the control group and 4.6% in the neovascular type AMD group, and this difference was statistically significant (p:0.04). This significant difference was present in both the early stage (%4.5) and late-stage (%4.6 ) (p:0.04, p:0.04). In addition, PD was determined 3.78 times greater among neovascular AMD patients(p:0.03), and significant association was present in both early-stage (3.72 times) and late-stage (3.82 times) (p:0.03, p:0.03). In the dry-type AMD group 2.7% PD was detected and there was no statistically significant difference compared to the control group (p > 0.05). This difference was not significant in the early stage (%2.3) or late-stage (%2.8) and also there was no significant association with dry-type AMD (p > 0.05). Also, unilateral and bilateral involvement in AMD was not associated with PD disease (p > 0.05). Conclusions Our study revealed the relationship between early and late-neovascular AMD and PD. However, this significant relationship was not detected between early and late-neovascular AMD and PD. Common pathways mediated by dopamine reduction in neovascular AMD and Parkinson's disease may explain the association of neovascular AMD with a higher risk of Parkinson's disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluation of the effect of Age-Related Macular Degeneration type and stage on the risk of Parkinson’s disease

Yaşar¹,

Gürlevik²,

Bilgeç³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…On the other hand, the pathogenesis of PD also shares several similarities with AMD. For both diseases, an increased incidence in elderly people, inflammatory processes and oxidative stress seem to play a major role ( Chen et al, 2021 ). In a study that was conducted by Choi et al, the association of AMD with AD and PD was investigated.…”

Section: Discussionmentioning

confidence: 99%

The function of p53 and its role in Alzheimer’s and Parkinson’s disease compared to age-related macular degeneration

et al. 2022

View full text Add to dashboard Cite

The protein p53 is the main human tumor suppressor. Since its discovery, extensive research has been conducted, which led to the general assumption that the purview of p53 is also essential for additional functions, apart from the prevention of carcinogenesis. In response to cellular stress and DNA damages, p53 constitutes the key point for the induction of various regulatory processes, determining whether the cell induces cell cycle arrest and DNA repair mechanisms or otherwise cell death. As an implication, aberrations from its normal functioning can lead to pathogeneses. To this day, neurodegenerative diseases are considered difficult to treat, which arises from the fact that in general the underlying pathological mechanisms are not well understood. Current research on brain and retina-related neurodegenerative disorders suggests that p53 plays an essential role in the progression of these conditions as well. In this review, we therefore compare the role and similarities of the tumor suppressor protein p53 in the pathogenesis of Alzheimer’s (AD) and Parkinson’s disease (PD), two of the most prevalent neurological diseases, to the age-related macular degeneration (AMD) which is among the most common forms of retinal degeneration.

show abstract

“…As such, some patients with unstable fixation or with neurological disorder cannot complete the whole microperimetric examination. This is for this reason that some studies excluded patients with cognitive deficit (Forshaw et al, 2021), as in addition to compliance, it is still debated in the literature how certain neurological disorder can affect the macula or are associated with an increased risk of AMD (Chen et al, 2021; Choi et al, 2020; Keenan et al, 2014; Wen et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

Microperimetry to predict disease progression in eyes at high risk of age‐related macular degeneration disease: The PREVISION study

Kodjikian

Creuzot‐Garcher

Korobelnik

et al. 2022

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose The aim of the present study was to determine whether microperimetric parameters could predict the progression of an eye at high risk of age‐related macular degeneration (AMD) at 24 months. Methods We conducted a multicentric prospective non‐comparative open‐label study including patients with one eye in stage 4 of the Age‐Related Eye Disease Study Group (AREDS) classification, and the other eye in AREDS stage 3 (study eye). A microperimetry examination (MAIA™, CenterVue, Padova, Italy) was performed at baseline and every 6 months during the 2‐year follow‐up. At the end of the follow‐up, each study eye was classified as ‘progressive’ (i.e. AREDS stage 4) or ‘non‐progressive’ (i.e. AREDS stage 3). Results A total of 147 patients were analysed, of which 30.6% progressed from AREDS stage 3 to stage 4. The microperimetry criterion ‘mean retinal sensitivity’ was significantly different at baseline between non‐progressive and progressive eyes (p = 0.022), with lower values for the latter. With a threshold for mean retinal sensitivity set at 24.7 dB, diagnostic sensitivity was 80% [95%CI (65.4–90.4)], specificity was 30.4% [95%CI (21.7–40.3)], positive predictive value was 33.6% [95%CI (24.8–43.4)], and negative predictive value was 77.5% [95%CI (61.5–89.2)]. In the multivariate analysis including microperimetric parameters and other routine ophthalmologic examinations, mean retinal sensitivity was the only predictive parameter statistically associated with progression (p = 0.0004). Conclusions Our findings are encouraging as regards the use of microperimetry, and mean retinal sensitivity value in particular, to predict the 2‐year risk of progression to AREDS stage 4 eye.

show abstract

Increased risk of Parkinson’s disease among patients with age-related macular degeneration

Cited by 13 publications

References 31 publications

Evaluation of the effect of Age-Related Macular Degeneration type and stage on the risk of Parkinson’s disease

Evaluation of the effect of Age-Related Macular Degeneration type and stage on the risk of Parkinson’s disease

The function of p53 and its role in Alzheimer’s and Parkinson’s disease compared to age-related macular degeneration

Microperimetry to predict disease progression in eyes at high risk of age‐related macular degeneration disease: The PREVISION study

Contact Info

Product

Resources

About